Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More
Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More
AUROBINDO PHARMA | SANOFI INDIA | AUROBINDO PHARMA/ SANOFI INDIA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 18.1 | 42.5 | 42.6% | View Chart |
P/BV | x | 3.9 | 8.6 | 45.2% | View Chart |
Dividend Yield | % | 0.3 | 1.0 | 26.7% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
AUROBINDO PHARMA Mar-19 |
SANOFI INDIA Dec-18 |
AUROBINDO PHARMA/ SANOFI INDIA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 830 | 6,840 | 12.1% | |
Low | Rs | 527 | 4,630 | 11.4% | |
Sales per share (Unadj.) | Rs | 333.9 | 1,203.1 | 27.8% | |
Earnings per share (Unadj.) | Rs | 40.4 | 165.3 | 24.4% | |
Cash flow per share (Unadj.) | Rs | 51.8 | 209.9 | 24.7% | |
Dividends per share (Unadj.) | Rs | 2.50 | 84.00 | 3.0% | |
Dividend yield (eoy) | % | 0.4 | 1.5 | 25.2% | |
Book value per share (Unadj.) | Rs | 237.1 | 963.6 | 24.6% | |
Shares outstanding (eoy) | m | 585.91 | 23.03 | 2,544.1% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 2.0 | 4.8 | 42.6% | |
Avg P/E ratio | x | 16.8 | 34.7 | 48.5% | |
P/CF ratio (eoy) | x | 13.1 | 27.3 | 48.0% | |
Price / Book Value ratio | x | 2.9 | 6.0 | 48.1% | |
Dividend payout | % | 6.2 | 50.8 | 12.2% | |
Avg Mkt Cap | Rs m | 397,569 | 132,078 | 301.0% | |
No. of employees | `000 | 17.9 | 3.3 | 540.9% | |
Total wages/salary | Rs m | 25,849 | 4,068 | 635.4% | |
Avg. sales/employee | Rs Th | 10,956.9 | 8,393.8 | 130.5% | |
Avg. wages/employee | Rs Th | 1,447.7 | 1,232.4 | 117.5% | |
Avg. net profit/employee | Rs Th | 1,324.3 | 1,153.0 | 114.9% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 195,636 | 27,708 | 706.1% | |
Other income | Rs m | 1,553 | 897 | 173.2% | |
Total revenues | Rs m | 197,189 | 28,605 | 689.4% | |
Gross profit | Rs m | 39,519 | 6,235 | 633.8% | |
Depreciation | Rs m | 6,680 | 1,027 | 650.4% | |
Interest | Rs m | 2,626 | 7 | 37,514.3% | |
Profit before tax | Rs m | 31,767 | 6,098 | 520.9% | |
Minority Interest | Rs m | 27 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -881 | 0 | - | |
Tax | Rs m | 7,269 | 2,292 | 317.1% | |
Profit after tax | Rs m | 23,645 | 3,806 | 621.3% | |
Gross profit margin | % | 20.2 | 22.5 | 89.8% | |
Effective tax rate | % | 22.9 | 37.6 | 60.9% | |
Net profit margin | % | 12.1 | 13.7 | 88.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 153,645 | 15,922 | 965.0% | |
Current liabilities | Rs m | 120,429 | 6,235 | 1,931.5% | |
Net working cap to sales | % | 17.0 | 35.0 | 48.6% | |
Current ratio | x | 1.3 | 2.6 | 50.0% | |
Inventory Days | Days | 135 | 64 | 212.4% | |
Debtors Days | Days | 64 | 21 | 305.2% | |
Net fixed assets | Rs m | 103,909 | 7,539 | 1,378.3% | |
Share capital | Rs m | 586 | 230 | 254.7% | |
"Free" reserves | Rs m | 138,322 | 21,962 | 629.8% | |
Net worth | Rs m | 138,908 | 22,192 | 625.9% | |
Long term debt | Rs m | 1,800 | 0 | - | |
Total assets | Rs m | 264,544 | 29,839 | 886.6% | |
Interest coverage | x | 13.1 | 872.1 | 1.5% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.7 | 0.9 | 79.6% | |
Return on assets | % | 9.9 | 12.8 | 77.7% | |
Return on equity | % | 17.0 | 17.2 | 99.3% | |
Return on capital | % | 23.8 | 27.5 | 86.6% | |
Exports to sales | % | 49.6 | 0 | - | |
Imports to sales | % | 18.8 | 0 | - | |
Exports (fob) | Rs m | 97,091 | NA | - | |
Imports (cif) | Rs m | 36,741 | NA | - | |
Fx inflow | Rs m | 97,316 | 7,587 | 1,282.7% | |
Fx outflow | Rs m | 40,589 | 7,145 | 568.1% | |
Net fx | Rs m | 56,727 | 442 | 12,834.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 16,220 | 3,739 | 433.8% | |
From Investments | Rs m | -28,768 | -731 | 3,935.5% | |
From Financial Activity | Rs m | 19,191 | -1,972 | -973.2% | |
Net Cashflow | Rs m | 6,656 | 1,036 | 642.5% |
Indian Promoters | % | 54.1 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 60.4 | - | |
Indian inst/Mut Fund | % | 8.0 | 14.4 | 55.2% | |
FIIs | % | 27.7 | 14.6 | 189.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 10.2 | 10.5 | 97.1% | |
Shareholders | 69,601 | 15,184 | 458.4% | ||
Pledged promoter(s) holding | % | 8.6 | 0.0 | - |
Compare AUROBINDO PHARMA With: VENUS REMEDIES ORCHID PHARMA NOVARTIS J.B.CHEMICALS PROCTER & GAMBLE HEALTH
Compare AUROBINDO PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian share markets rose for the third straight session today, tracking gains in US peers. The Nikkei is trading up by 0.7% and the Hang Seng is trading up by 0.1%.
For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More